Becoming.

The benefit of adding bevacizumab to FOLFOX for patients with initially unresectable liver metastases from RAS-mutated colorectal cancer is uncertain. In the BECOME trial, 241 such patients received mFOLFOX6 with or without the addition of bevacizumab. The idea here was to convert patients to resectable without increasing surgical complications. Adding bevacizumab increased the response rate from 37→ 55%, which resulted in a significant increase in R0 resections from 6→ 22%. In addition, there was a significant increase in both progression-free and over survival. TBL: In BECOME, adding bevacizumab to mFOLFOX6 increased the resection rate and improved survival outcomes for patients with initially unresectable, RAS-mutated colorectal cancer liver metastases. | Tang, J Clin Oncol 2020

Comments

Popular Posts